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Disorders of male reproductive health are
common and perhaps increasing in the
Western world (Sharpe and Skakkebaek 2003;
Toppari et al. 1996). These include cryp-
torchidism and hypospadias, which present at
birth, and low sperm counts and testicular
germ cell cancer, which manifest in young
adulthood. Evidence suggests that these dis-
orders may have a common origin in fetal life
(Sharpe and Skakkebaek 2003; Skakkebaek
et al. 2001). Based on this evidence, these dis-
orders have been hypothesized to constitute a
testicular dysgenesis syndrome (TDS), which
results from abnormal development of the
testis and consequent malfunction of the
Leydig cells (LC) and/or Sertoli cells (SC)
during male sexual differentiation (Sharpe and
Skakkebaek 2003; Skakkebaek et al. 2001). 
Certain phthalate esters such as di(n-
butyl) phthalate (DBP) have been shown in
rats to interfere with normal development of
the testis and reproductive tract when expo-
sure occurs during gestation (Barlow and
Foster 2003; Ema et al. 1998, 2000; Fisher
et al. 2003; Gray et al. 1999; Mylchreest et al.
1998, 1999, 2000), resulting in postnatal
downstream disorders that are similar to
those reported in human TDS, that is, cryp-
torchidism, hypospadias, impaired spermato-
genesis, and reduced male fertility. Fetal
exposure of male rats to DBP therefore has
potential as an animal model in which to
explore the events in the fetal testis that give
rise to TDS (Fisher et al. 2003). In searching
for such mechanisms, various phthalate-
induced changes in the fetal testis have been
reported, namely the occurrence of multi-
nucleated gonocytes (MNGs), abnormal LC
aggregation, decreased testicular testosterone
levels, and decreased insulin-like factor 3
mRNA/protein expression (Fisher et al. 2003;
Mahood et al. 2005; McKinnell et al. 2005;
Parks et al. 2000; Shultz et al. 2001; Wilson
et al. 2004). We have also shown that in utero
exposure of rats to 500 mg/kg DBP causes
postnatal development of focal areas of dys-
genesis, comprising malformed seminiferous
cords/tubules with intracordal/intratubular
LC and immature SC, within otherwise nor-
mal testes that exhibit complete spermato-
genesis (Fisher et al. 2003; Mahood et al.
2005, 2006); similar changes have been
reported in TDS (testicular cancer) patients
(Hoei-Hansen et al. 2003; Sharpe 2006). 
The similarity between DBP-induced
TDS-like disorders in rats and the relatively
high prevalence of TDS disorders in humans
has raised the question of whether DBP, or
other phthalates, might contribute causally to
human TDS. This possibility arises because
of the widespread exposure of humans to
DBP and other phthalates (Hauser et al.
2004; Rudel et al. 2003; Schettler 2006),
although there is only one piece of published
evidence to indicate that phthalate exposure
during pregnancy might cause changes in the
male offspring that are analogous to those
reported in rats (Swan et al. 2005). An
important issue in this debate is that the low-
est doses (50–100 mg/kg/day) of DBP, or
other phthalates, that have been shown to
cause abnormal changes in rats, namely
reduced anogenital distance (AGD) and nip-
ple retention (Mylchreest et al. 2000; Zhang
et al. 2004), are considerably higher than
reported exposure levels in the human popu-
lation (Hauser and Calafat 2005; Koch et al.
2003; Silva et al. 2004). Additionally, most of
the end points evaluated in rat studies, such
as AGD (Barlow and Foster 2003; Barlow
et al. 2004; Carruthers and Foster 2005; Ema
et al. 1998, 2000; Mylchreest et al. 1998,
1999, 2000; Zhang et al. 2004) and nipple
retention (Barlow and Foster 2003; Barlow
et al. 2004; Carruthers and Foster 2005;
Mylchreest et al. 1999, 2000) are difﬁcult to
relate directly to TDS in humans.
Therefore, the aim of the present study was
to evaluate end points in our in vivo rat model
of TDS that can be related more obviously to
similar TDS disorders in humans, and to
explore the DBP dose sensitivity of these end
points. It was also important that all of these
end points could be quantifiable to enable
objective measurement. The end points that
we chose included actual end points of TDS
(infertility, cryptorchidism), together with
indicators within the testis of dysgenesis
(occurrence of dysgenetic areas, MNGs, and
abnormal LC aggregation). Other fetal end
points, such as testis weight and testicular
testosterone levels, were also evaluated. Where
relevant, these end points were investigated in
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BACKGROUND: Fetal exposure of male rats to di(n-butyl) phthalate (DBP) induces reproductive
disorders similar to those in human testicular dysgenesis syndrome (TDS), including infertility,
cryptorchidism, focal “dysgenetic areas,” and Sertoli cell–only tubules in the adult testis. Humans
are widely exposed to DBP, but at much lower levels than those causing adverse effects in rats. 
OBJECTIVES: The objective of this study was to evaluate end points affected by DBP action in rats
in fetal and adult life that are relevant to human TDS, and to compare their dose sensitivity.
METHODS: Pregnant rats were gavaged daily with corn oil (control) or with 4, 20, 100, or
500 mg/kg DBP. We examined adult end points of TDS (infertility, cryptorchidism) and indica-
tors within the fetal testis of dysgenesis [abnormal Leydig cell (LC) aggregation, multinucleated
gonocytes (MNGs)], as well as conditions that may result from these indicators in adulthood
(occurrence of focal dysgenetic areas). Fetal testis weight and testicular testosterone levels were also
evaluated. 
RESULTS: The fetal end points analyzed (testicular testosterone levels, abnormal LC aggregation,
occurrence of MNGs) were most sensitive to disruption by DBP, as all were signiﬁcantly affected at
a dose of 100 mg/kg/day DBP, with a trend toward effects occurring at 20 mg/kg/day DBP; adult
end points were affected consistently only by 500 mg/kg/day DBP. 
CONCLUSIONS: The fetal end points we evaluated can be objectively quantiﬁed and may prove help-
ful in evaluating the health risk of exposure to DBP and other phthalates, as well as identifying DBP-
sensitive fetal events that have adult consequences/end points that are identiﬁable in human TDS. 
KEY WORDS: cryptorchidism, di(n-butyl) phthalate, dose response, dose sensitivity, dysgenetic areas,
infertility, Leydig cell aggregation, male reproductive development, multinucleated gonocytes,
testicular dysgenesis syndrome. Environ Health Perspect 115(suppl 1):55–61 (2007).
doi:10.1289/ehp.9366 available via http://dx.doi.org/ [Online 8 June 2007]both fetal and postnatal life, and four different
doses of DBP (4, 20, 100, and 500 mg/kg/day)
were used. Our results show that it is the
fetal end points that are the most sensitive to
DBP action.
Materials and Methods
Animals, treatments, sample collection, and
processing. Wistar rats were maintained in
our own animal facility according to UK
Home Office guidelines [Animal (Scientific
Procedures) Act 1986], and were fed a soy-
free breeding diet (SDS, Dundee, Scotland).
Time-mated females [day of vaginal plug =
gestation day (GD) 0.5] were treated from
GD13.5 to either GD20.5 (fetal samples) or
GD21.5 (postnatal tissue) with either 0 (con-
trol), 4, 20, 100, or 500 mg/kg DBP (Sigma,
Dorset, UK) in 1 mL/kg corn oil adminis-
tered daily by oral gavage. The DBP was 99%
pure according to the supplier. Corn oil was
obtained from a supermarket and was used as
obtained.
Fetal samples. Control and DBP-treated
pregnant dams were killed by inhalation of
carbon dioxide followed by cervical dislocation
on GD21.5. Fetuses were removed, decapi-
tated, and placed in ice-cold phosphate-
buffered saline (PBS; Sigma). Testes were
removed via microdissection, ﬁxed for 1 hr in
Bouins ﬁxative, and then transferred to 70%
ethanol. Fixed testes were weighed and then
processed into paraffin wax using standard
methods. One or more male fetuses from each
litter were subsequently used for the quantita-
tive and immunohistochemical studies
described below; selection of fetuses for fur-
ther study was random 
Adult samples. Male rats 90 days of age
were killed by inhalation of CO2 followed by
cervical dislocation. Testes were carefully
inspected for normality of the epididymis and
vas deferens and then removed, weighed,
ﬁxed for 5–6 hr in Bouins ﬁxative, and then
transferred into 70% ethanol. Testes were
halved after approximately 3 hr ﬁxation to aid
penetration of the fixative. Testes were then
further cut into four to eight blocks, depend-
ing on size, and embedded in paraffin as
described above. At necropsy, testicular posi-
tion was classiﬁed as high abdominal (at level
of the kidney), mid-abdominal, inguinal, or
scrotal, which enabled classification of testes
into cryptorchid or scrotal groups. In con-
trols, all testes were scrotal in position.
Individual testes from adult animals that
exhibited any gross epididymal lesions were
excluded from histologic analysis to avoid
possible confounding effects of this change on
testicular morphology (Barlow and Foster
2003; Mylchreest et al. 1998); this applied to
two testes from a total of 13 males. Before
dissection, the adult male rats underwent a
fertility test. This involved each male rat
being housed singly for 1 week with a female
rat of proven fertility. Males were classed as
fertile if offspring were produced.
For the studies above, animals were treated
humanely and with regard for alleviation of suf-
fering. All studies were performed according to
the Animal (Scientiﬁc Procedures) Act (1986)
under Project Licence approval by the UK
Home Ofﬁce.
Testicular testosterone analysis. Testicular
testosterone levels were measured by radio-
immunoassay, as described previously (Fisher
et al. 2003), on GD21.5 in individual testes
from males from four to six litters per treat-
ment group. After dissection, testes were snap
frozen on dry ice and stored at –70°C before
analysis. Testes were defrosted and homoge-
nized individually in 0.5 mL PBS; an aliquot
of this solution was then extracted with 2 mL
diethyl ether, shaken for 5 min, and then
placed in a bath of methanol cooled with dry
ice. The nonaqueous portion of the extract
was then decanted, dried overnight in a fume
hood, and reconstituted in assay buffer. The
limit of detection of the assay was 40 pg/testis.
Immunohistochemistry. Specific proteins
were detected by immunohistochemistry using
methods that have been described previously
(Fisher et al. 2003). Sections (5 µm) were
mounted onto coated slides (BDH Chemicals,
Poole, UK), dewaxed, and rehydrated. Slides
were incubated in 3% (vol/vol) hydrogen per-
oxide in methanol to block endogenous
peroxidase activity, then washed in Tris-
buffered saline (TBS: 0.05 M Tris, 0.85%
NaCl, pH 7.4 at room temperature). Non-
specific binding sites were blocked with an
appropriate normal serum diluted 1:5 in TBS
containing 5% bovine serum albumin
(Sigma). Sections were incubated with the pri-
mary antibodies 3β-hydroxysteroid dehydro-
genase (3β-HSD; 1:4000; gift from I. Mason,
Edinburgh, UK) or smooth muscle actin
(SMA, 1:2000; Sigma) overnight at 4°C.
The next morning, slides were incubated
30 min with the appropriate secondary anti-
body conjugated to biotin, at a dilution of
1:500 (rabbit anti-mouse or swine anti-rabbit;
DAKO, Cambridgeshire, UK). The biotiny-
lated antibody was linked to horseradish peroxi-
dase (HRP) by 30-min incubation with
avidin-biotin–HRP complex (ABC-HRP;
DAKO). Antibody localization was determined
by application of diaminobenzidine (liquid
DAB+; DAKO) until staining in control sec-
tions was optimal; the reaction was stopped by
immersing slides in distilled water. Slides were
counterstained with hematoxylin, dehydrated,
and mounted using Pertex mounting media
(Cell Path; Hemel Hempstead, UK).
Analysis of MNGs. We identiﬁed MNGs
using toluidine blue staining of GD21.5 testis
sections from one or more testes from animals
selected at random from ﬁve to nine litters per
treatment group. Slides were dewaxed and
rehydrated as for immunohistochemistry. The
toluidine blue stain (BDH Chemicals) was ﬁl-
tered and applied to slides at a 50% dilution
with distilled water. Once staining was optimal
the slides were immersed in distilled water and
then dehydrated and mounted. To analyze the
occurrence of MNGs, we used an Olympus
BH-2 microscope (Olympus Optical, London,
UK) ﬁtted with a Prior automatic stage (Prior
Scientiﬁc Instruments Ltd, Cambridge, UK).
One complete testis cross-section from each
animal was analyzed, and the percentage of
seminiferous cord cross-sections that con-
tained one or more MNGs was recorded. We
did not record the number of MNGs per cord
or the number of nuclei per MNG. The ana-
lyzer was blinded with respect to the treatment
status of animals.
LC cluster analysis. LC aggregation was
objectively quantified using previously
described methods (Mahood et al. 2005).
Testes from one or more fetuses per litter at
GD21.5, from ﬁve to six litters per treatment
group, were randomly selected and serially
sectioned. DBP treatment results in unequal
distribution of LC throughout the testis due
to their abnormal migration/aggregation into
more central regions (Mahood et al. 2005).
To avoid sampling errors because of this
unequal distribution, we selected three sec-
tions per testis that corresponded to uniform
intervals through the serially sectioned testis
(25, 50, and 75% intervals, which were thus
20–30 sections apart from each other); these
sections were immunostained for 3β-HSD as
described above. 
Quantification of LC clustering in these
sections was undertaken using Image-Pro Plus
4.5.1 software and equipment (Media
Cybernetics UK, Wokingham, Berkshire, UK).
Specimens immunostained for 3β-HSD were
of sufﬁcient homogeneity, high contrast, and
low background to allow computer-assisted
thresholding and subsequent computer-assisted
counting of LC (3β-HSD–immunopositive)
clusters and determination of LC cluster area.
Digital images of complete testis sections were
captured at ×40 magniﬁcation. The software
was used to trace around each section, creating
an area of interest; the area of each section
could then be calculated. Computer-assisted
thresholding was then used to identify and
analyze clusters of 3β-HSD–immunopositive
cells, generating data on cluster number and
the proportion of each section occupied by LC
clusters, as described in detail elsewhere
(Mahood et al. 2005). To take account of the
decrease in LC size in DBP-exposed males
(Mahood et al. 2005), each LC cluster was
expressed as a percentage of the total LC clus-
ter area in each animal. Clusters were then
arbitrarily assigned to one of three groups:
small clusters, accounting for ≤ 5% of the total
Mahood et al.
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accounting for 5.1–14.9%; and large clusters,
which individually accounted for ≥ 15% of the
total LC cluster area per testis.
Incidence of dysgenesis. We assessed the
incidence of dysgenesis in each of the treat-
ment groups in adult male rats by visual analy-
sis of SMA immunostained sections from four
to eight blocks per testis for each animal.
Sections were checked for the occurrence of
Sertoli cell–only (SCO) tubules and focal dys-
genetic areas in each testis (cryptorchid and
scrotal). Testes were obtained from one or
more animals from at least ﬁve separate litters
from each treatment group. 
Image capture. Images were examined and
photographed using a Provis microscope
(Olympus Optical, London, UK) ﬁtted with a
Kodak DCS330 digital camera (Eastman
Kodak, Rochester, NY, USA). Images were
compiled using Photoshop 7.0 (Adobe Systems
Inc., Mountain View, CA, USA).
Statistical analysis. We used data for each
of the fetal end points and for adult testis
weight to derive a mean value for each litter;
litter means ± SE were then computed and
used for statistical analyses. Data were analyzed
by one-way analysis of variance followed by the
Bonferroni post-test. The incidence of infertil-
ity, cryptorchidism, SCO tubules, and focal
dysgenetic areas in adult animals was analyzed
using Fisher’s exact test. For the latter datasets,
we analyzed both data from individual animals
and litter means, in view of the wide variation
(0–100%) in incidence between different lit-
ters for some of the measured end points. Data
for LC cluster number per testis were log trans-
formed before statistical analysis to normalize
variances. All analyses were performed using
GraphPad Prism (version 4; GraphPad
Software Inc., San Diego, CA, USA). 
Results
Infertility, cryptorchidism, testis weight, and
testicular testosterone. In adult animals pre-
natally exposed to 500 mg/kg DBP, we found
a 75% infertility rate, dropping to 33% in the
100-mg/kg group and to 14% in the 20-
mg/kg group. However, only the 500 mg/kg
DBP treatment group had significantly
reduced fertility compared with the controls
when data were analyzed for individual ani-
mals (Figure 1A) or when analyzed using inci-
dence of infertility per litter (p = 0.03). The
500-mg/kg DBP treatment group was also the
only treatment group to have a significantly
elevated incidence of cryptorchidism com-
pared with the control group, with 90% of
animals exhibiting either unilateral or bilateral
cryptorchidism compared with no animals in
the control group (Figure 1B); this difference
was equally evident when data were analyzed
as incidence of cryptorchidism per litter
(p = 0.005). In all other treatment groups, we
found only one case of cryptorchidism (unilat-
eral), and this was in the group exposed to
100 mg/kg DBP. Exposure to 500 mg/kg
DBP during gestation resulted in a signiﬁcant
decrease in testis weight compared with con-
trol animals both at GD21.5 and in adult-
hood (Figure 2A,B), although the reduction in
adulthood was attributable solely to the high
incidence of cryptorchid testes (Figure 2C).
Animals exposed to 4, 20, or 100 mg/kg DBP
did not show any signiﬁcant change in testis
weight at either GD21.5 (Figure 2A) or in
adulthood (Figure 2B). Testicular testosterone
levels in GD21.5 animals were significantly
decreased in both the 500- and 100-mg/kg
DBP treatment groups compared with control
values (Figure 3). We found no significant
effect of DBP treatment on fetal body weight
or on litter size (data not shown). 
Occurrence of MNGs at GD21.5. All
treatment groups, including the control
group, had MNGs within the seminiferous
cords at GD21.5 (Figure 4A,B). Prenatal
exposure to either 500 or 100 mg/kg DBP
resulted in a signiﬁcant increase in the occur-
rence of MNGs compared with controls; also,
DBP dose sensitivity and testicular dysgenesis
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Figure 1. Incidence of infertility (A) and cryptorchidism (B) in adult male rats exposed in utero (GD13.5–
GD21.5) to corn oil (control) or DBP. Values shown in parentheses are the number of infertile/fertile ani-
mals (A) and the number of animals with either unilateral or bilateral cryptorchid/normal testis position (B).
Animals were derived from five to seven litters except for the 20 mg/kg DBP group, which was derived
from three litters. 
#p < 0.0001 compared with control.
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Figure 2. Testis weights at GD21.5 (A) or in adulthood (B) in male rats exposed in utero (GD13.5– GD21.5) to corn oil (control) or DBP. (C) Breakdown comparison of
cryptorchid and scrotal testis weights from adult male rats exposed in utero to 500 mg/kg DBP. Values are litter mean ± SE for 4–16 litters per treatment group
(based on 28–98 animals/group). 
#p < 0.001 compared with respective control s. ##p < 0.0001 compared with cryptorchid testis weights.
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Figure 3. Testicular testosterone levels at GD21.5 in
animals exposed in utero (GD13.5–GD20.5) to corn
oil (control) or DBP. Testosterone values are litter
mean ± SE for four to six litters per group. 
*p < 0.05. #p < 0.001 compared with control.
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DBP concentration (mg/kg/day)we found an increase in the occurrence of
MNGs in animals exposed to 20 mg/kg DBP
(Figure 4C), although it was not statistically
signiﬁcant.
LC clustering/aggregation at GD21.5.
Changes in LC distribution were obvious in
both the 100- and 500-mg/kg DBP treatment
groups (Figure 5D,E) compared with controls
(Figure 5A); these changes were most pro-
nounced in the highest dose group, with large
LC clusters being evident in the center of the
testes (Figure 5E). LC distribution in testis sec-
tions from the 4- and 20-mg/kg treatment
groups were not obviously different from con-
trols (Figures 5B,C). Objective analysis of LC
aggregation revealed a significant decrease in
total LC cluster number per testis section in
animals exposed to either 100 or 500 mg/kg
DBP (Figure 6A). This pattern was similarly
reﬂected in the data for the percentage of total
cluster area accounted for by small clusters
(Figure 6B). LC clusters of medium size were
evident in all treatment groups but were only
signiﬁcantly increased above control values in
the 100-mg/kg DBP group (Figure 6C). The
occurrence of large LC clusters was evident only
in groups of males exposed to 20, 100, or
500 mg/kg DBP (Figure 6D). However, com-
pared with control animals, the number of large
LC clusters was signiﬁcantly increased only in
the 500-mg/kg group, in which approximately
40% of the total LC cluster area was accounted
for by clusters of this size (Figure 6D).
Incidence of focal dysgenesis in adulthood.
Visual analysis of SMA-immunostained testis
sections from each treatment group revealed
that all cryptorchid testes examined from the
500-and 100-mg/kg DBP groups had SCO
tubules present (Table 1). Of the 11 cryp-
torchid testes examined in the 500-mg/kg
DBP group, 7 had one or more focal dys-
genetic areas. In testes from control animals,
we found neither SCO tubules nor areas of
focal dysgenesis (Figure 7A). SCO tubules
were found in all DBP-exposed groups except
the 4 mg/kg treatment group (Table 1).
However, not all testes examined in each group
had SCO tubules present. Interestingly, we
found that a similar number of testes in the
two highest dose groups (500 and 100 mg/kg)
had SCO tubules (~ 66% of testes examined);
this incidence was statistically signiﬁcant when
data were analyzed for individual animals
(Table 1) or based on the incidence per litter
(i.e., any animal per litter exhibiting SCO
tubules; p = 0.04). Focal dysgenetic areas were
detected only in the 500- and 100-mg/kg DBP
animals (Figure 7B,C); 55% of testes examined
in the 500-mg/kg group and approximately
33% in the 100-mg/kg dose group had areas of
dysgenesis present. However, only the inci-
dence of dsygenetic areas in the 500-mg/kg
DBP group achieved statistical significance
when analyzed for individual animals
(Table 1); this was of borderline signiﬁcance
when evaluated per litter (p ~ 0.05).
Discussion
We and others have shown that fetal exposure
of male rats to DBP, or certain other phtha-
lates, results in a high incidence of disorders
such as cryptorchidism, hypospadias, and infer-
tility (Barlow and Foster 2003; Ema et al.
1998, 2000; Fisher et al. 2003; Gray et al.
1999; Mylchreest et al. 1998, 1999, 2000).
These disorders are collectively similar to those
reported in human TDS patients, and as such,
the focus of the present study was to investigate
DBP-induced changes in fetal life and in adult-
hood that were considered relevant to TDS.
To date, studies investigating the effects of
DBP on male reproductive development have
used end points that may be relevant to human
TDS (occurrence of cryptorchidism, decreased
fertility), or that are not relevant (nipple
retention in male rats), or that are presently
of uncertain relevance (decreased AGD)
(Barlow and Foster 2003; Barlow et al. 2004;
Carruthers and Foster 2005; Ema et al. 1998,
2000; Mylchreest et al. 1998, 1999, 2000;
Zhang et al. 2004). Similarly, changes in gene
and protein expression after DBP exposure,
which have been found to be more sensitive to
the effects of DBP (Lehmann et al. 2004), can-
not be related directly to TDS other than
when the changes relate to expression of genes
involved in LC hormone production. These
include reduction in the expression of genes
and proteins involved in cholesterol transport
and steroidogenesis leading to a concomitant
Mahood et al.
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Figure 4. Occurrence of MNGs (arrows) in representative photomicrographs of testicular sections collected on GD21.5 from rats exposed in utero (GD13.5– GD20.5)
to corn oil (control; A) or 500 mg/kg/day DBP (B). Tissues were stained with toluidine blue; bar = 50 µm. (C) Percentage of seminiferous cords exhibiting MNGs on
GD21.5 in animals exposed in utero to DBP (mg/kg/day); values are litter mean ± SE for ﬁve to nine litters per treatment group. 
#p < 0.001 compared with control.
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Figure 5. Representative photomicrographs illustrating the change in distribution of Leydig cells (3β-HSD-positive, brown) in the testes of GD21.5 animals exposed
in utero (GD13.5– GD20.5) to corn oil (control; A) or DBP doses of (B) 4, (C) 20, (D) 100, or (E) 500 mg/kg/day. Tissues were counterstained with hematoxylin;
bar = 0.5 mm.
A B C D Edecrease in fetal testicular testosterone levels, as
seen in the present study at doses ≥ 100 mg/kg
DBP, and as has also been reported to occur at
doses as low as 50 mg/kg/day DBP (Barlow
et al. 2003; Lehmann et al. 2004; Shultz et al.
2001). The reduction in AGD and the reten-
tion of nipples in male rats exposed during ges-
tation to DBP are presumed to be effects of
DBP that are secondary to decreased testicular
testosterone production (Fisher et al. 2003;
Mahood et al. 2005; Mylchreest et al. 2002;
Parks et al. 2000; Shultz et al. 2001). For this
reason, and because dose–response studies
using these end points are already well reported
(Mylchreest et al. 1998, 1999, 2000; Zhang
et al. 2004), we did not measure AGD or nip-
ple retention in the present study. Instead, our
aim was to evaluate objectively quantifiable
end points that we considered of direct rele-
vance to either the manifestation (adult end
points) or origins (fetal end points) of TDS. 
Our results indicate that it is the fetal end
points analyzed (testicular testosterone levels,
abnormal LC aggregation, occurrence of
MNGs) that appear to be most sensitive to
disruption by DBP. All three of these end
points were affected significantly by a DBP
dose of 100 mg/kg/day; it also appears that a
dose of 20 mg/kg/day probably also has an
effect on some of these parameters, although
this did not achieve statistical significance.
Only exposure to 500 mg/kg/day DBP
resulted in a significant decrease in testis
weight in fetal and adult life, but even in the
latter, the observed decrease was secondary to
the occurrence of cryptorchidism. Thus, segre-
gation of adult testis weights into scrotal and
cryptorchid testes in the 500-mg/kg dose
group showed that the decrease in mean testis
weights seen at this dose was due completely
to the small size of the cryptorchid testes in
these animals. In this regard, it is also notable
that in the 500-mg/kg/day DBP treatment
group, adult scrotal testes, which were normal
in weight and largely normal for gross mor-
phology and completeness of spermatogenesis,
clearly exhibited focal abnormalities (focal dys-
genesis, SCO tubules). The other postnatal
end points investigated in this study (inci-
dence of infertility and cryptorchidism) were
significantly increased above control levels
only in the 500 mg/kg/day group, indicating
that these are insensitive end points to use
when investigating the effects of lower dose
DBP exposure in fetal life.
We have recently proposed a model to
explain the origin of dysgenetic areas and
DBP dose sensitivity and testicular dysgenesis
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Figure 6. Number and distribution of LC clusters in testes collected on GD21.5 from male rats exposed
in utero (GD13.5–GD20.5) to corn oil (control) or to DBP. The number of LC clusters per testis section (A) and
the percentage occurrence of small (B), medium (C), and large (D) LC clusters are shown for each treatment
group. Values shown are litter mean ± SE for ﬁve to six litters per treatment group. Small clusters account for
≤ 5% of the total LC cluster area per testis, medium clusters for 5.1–14.9%, and large clusters for ≥ 15%.
**p < 0.01. #p < 0.001 compared with respective control values.
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Table 1. Incidence of SCO tubules and dysgenetic areas in the testes of adult male rats exposed in utero
(GD13.5– GD21.5) to corn oil (control) or to varying doses of DBP (mg/kg/day).
Cryptorchid testes Scrotal testes
No.  SCO tubules  No. SCO tubules  Dysgenetic 
DBP (mg/kg/day) analyzed present analyzed present areas
0 (control) 0 — 9 No (0/9) No (0/9)
500 11 Yes (11/11)a 9 Yes (6/9)b  Yes (5/9)c 
100 1 Yes 12 Yes (8/12)d Yes (4/12)
20 0 — 5 Yes (1/5) No (0/5)
4 0 — 11 No (0/11) No (0/11)
Numbers in parentheses indicate the number of testes that exhibited either SCO tubules or dysgenetic areas of the total num-
ber of testes analyzed. Each scrotal and cryptorchid testis analyzed was from a different animal and represented at least three
different litters; seven of the analyzed cryptorchid testes were from unilaterally crytorchid animals for which the correspond-
ing scrotal testis was also analyzed.
aSeven of these 11 testes had dysgenetic areas. bp = 0.009. c p = 0.029. dp = 0.005.
Figure 7. Photomicrographs of scrotal testes from adult rats exposed in utero to (A) corn oil (control), or to DBP doses of (B) 500 or (C) 100 mg/kg/day DBP.
Although the majority of each cross-section of scrotal testes in DBP-exposed animals had normal seminiferous tubules, some animals exhibited one or more
focal dysgenetic areas comprising malformed seminiferous tubules as visualized by immunostaining for SMA to identify peritubular myoid cells. Note the occur-
rence of unusually large numbers of LCs surrounding the malformed tubules (B,C). Bar = 100 µm.
A B CSCO tubules formed in the testes of DBP-
exposed rats (Mahood et al. 2005, 2006). This
model hypothesizes that DBP-induced abnor-
mal migration and aggregation of LCs within
the fetal testis “traps” isolated SC, gonocytes,
and presumably peritubular myoid cells within
them (Fisher et al. 2003). Postnatally, after
cessation of DBP treatment, these non-
segregated clusters of cells then try to form
seminiferous cords; we propose that this
process results in the formation of dysgenetic
areas focally within the testes, surrounded by
otherwise normal tissue with complete sper-
matogenesis (in scrotal testes). The results
from the present dose–response study support
our proposed model because dysgenetic areas
were seen in adulthood following fetal expo-
sure to either 100 or 500 mg/kg/day DBP,
and it is at these doses that abnormal LC
aggregation was induced in fetal life. The
dose-dependent nature of fetal LC aggregation
was grossly evident in the testicular images
immunostained for 3β-HSD (Figure 5) as well
as after objective quantification using image
analysis. An increase in the occurrence of
MNGs was also observed at GD21.5 in the
100 mg/kg and the 500 mg/kg DBP dose
groups (Figure 4), although it is still unknown
if these abnormal germ cells contribute to the
dysgenetic phenotype of the adult DBP-
exposed animals and what their precise rele-
vance, if any, is to human TDS (Ferrara et al.
2006). The cause of MNGs is unknown, but
it is not due to abnormal/incomplete cell divi-
sion because it occurs at ages when the germ
cells are quiescent and not dividing (GD19.5–
GD21.5); we have confirmed this using a
number of different proliferation markers
(Ferrara et al. 2006). It seems likely that the
mechanisms underlying the induction of
MNGs are separate from those involved in the
formation of focal dysgenetic areas, because
MNGs occur throughout the fetal testis and
are equally evident in normally formed semi-
niferous cords as in areas destined to form dys-
genetic areas (Fisher et al. 2003).
A dose–response study investigating
changes in gene and protein expression in the
fetal testis established a dose of DBP of
50 mg/kg/day as the lowest observed adverse
effect level (LOAEL), and 10 mg/kg/day as the
no observed adverse effect level (NOAEL)
(Lehmann et al. 2004). In the present study,
we did not use a dose of 50 mg/kg/day, but we
have established a LOAEL of 100 mg/kg/day
for fetal end points and a NOAEL of
20 mg/kg/day, although there does appear to
be a clear trend towards effects on the occur-
rence of MNGs at a dose of 20 mg/kg/day
DBP; this may have reached statistical signiﬁ-
cance if more litters had been studied. Taken
together, the available data suggests that doses
of 20–50 mg/kg/day DBP may cause changes
in fetal rat testis development that are of likely
relevance to the postulated origins of human
TDS disorders (i.e., disruption of fetal testis
organization/function. These levels of expo-
sure are still much higher than the suggested
environmental exposure levels of the human
population (Hauser and Calafat 2005; Koch
et al. 2003; Silva et al. 2004). Although this
contrast suggests, at face value, that the
human male fetus is at low risk from exposure
to DBP alone, it is important to consider the
combined risk of exposure to DBP and other
phthalates that can exert similar effects (e.g.,
diethylhexyl phthalate), or indeed other
endocrine-disrupting chemicals. Recent stud-
ies have reported that pairs of phthalates
(Borch et al. 2004) or combination of a
phthalate with another anti-androgen with a
different mode of action (Hotchkiss et al.
2004) produce dose-additive effects on male
reproductive malformations in rats. Therefore,
studies investigating the dose–response rela-
tionships and dose-additive effects of phtha-
lates and other endocrine-disrupting chemicals
on male reproductive development need to be
a focus of future research in order to fully
evaluate the risk of human exposure. 
We hope that the new fetal end points
described in the present study (occurrence of
MNGs and abnormal LC aggregation), which
can be objectively quantiﬁed, will prove a use-
ful resource in future studies. It can be argued
that the fetal occurrence of MNGs induced
by DBP is irrelevant because it has no known
direct consequences for the fetus (which does
not reproduce) or the adult. However,
because MNGs may reflect altered SC func-
tion in fetal life (Ferrara et al. 2006), and it is
the number (and function) of the SC that
predetermines sperm count and fertility in
adulthood, MNGs may provide a sensitive
(indirect) measure of such effects. Similarly,
the occurrence of abnormal LC aggregation
in the fetal testis is potentially of direct evi-
dence to adult testis function, as our evidence
suggests that it is an important cause of SCO
tubules and focal dysgenetic areas in the testis
in adulthood (Mahood et al. 2006). As the
latter features are clearly relevant to human
TDS (Hoei-Hansen et al. 2003; Sharpe
2006), it would be sensible to concentrate on
such end points or to identify other fetal end
points that have proven consequences that are
detectable in adulthood. 
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